Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

Todd Neale

May 18, 2021

News Conference News EuroPCR 2020

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

Michael O'Riordan

June 30, 2020

News Conference News EuroPCR 2019

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

L.A. McKeown

May 31, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Michael O'Riordan

May 24, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

Presentation EuroPCR 2017

Prasugrel, Ticagrelor and Clopidogrel in PPCI for STEMI: An Analysis of Comparative Clinical Outcomes from the UK BCIS National Registry

Presenter: Mamas A. Mamas

May 22, 2017

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Caitlin E. Cox

May 22, 2017

News Conference News EuroPCR 2016

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

Michael O'Riordan

May 17, 2016

$Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial$

Presentation EuroPCR 2014

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Presenter: Uwe Zeymer

May 21, 2014

News Conference News EuroPCR 2014

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Yael L. Maxwell

May 21, 2014

News Conference News

POST-AMI: Postconditioning Not Helpful, Possibly Harmful in STEMI Patients

Caitlin E. Cox

May 19, 2011

News Conference News

Different Agents Show Potential as Adjuncts to PCI

Jason Kahn

May 19, 2011

News Conference News

RECLOSE 2-ACS: Poor Responders Show Poor Outcomes Despite Higher Clopidogrel Dose

Caitlin E. Cox

May 18, 2011

Advertisement

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

Tirofiban Provides Better Platelet Inhibition Than Cangrelor in STEMI Patients

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Prasugrel, Ticagrelor and Clopidogrel in PPCI for STEMI: An Analysis of Comparative Clinical Outcomes from the UK BCIS National Registry

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Last Window for BMS Closes as LEADERS-FREE Supports DES in High-Bleeding-Risk ACS

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

POST-AMI: Postconditioning Not Helpful, Possibly Harmful in STEMI Patients

Different Agents Show Potential as Adjuncts to PCI

RECLOSE 2-ACS: Poor Responders Show Poor Outcomes Despite Higher Clopidogrel Dose

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content